Cargando…
Mycophenolate mofetil as second line immunosuppressant in myasthenia gravis - a long-term prospective open-label study
BACKGROUND: The preferred immunosuppressive drug for long term treatment of myasthenia gravis (MG) is azathioprine (AZA). Mycophenolate mofetil (MMF) was suggested as an effective and safe second line alternative to AZA. METHODS: In a prospective open-label study, 11 patients with acetylcholine rece...
Autores principales: | Hanisch, F, Wendt, M, Zierz, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352168/ https://www.ncbi.nlm.nih.gov/pubmed/19666397 http://dx.doi.org/10.1186/2047-783X-14-8-364 |
Ejemplares similares
-
Mycophenolate mofetil for myasthenia gravis: a clear and present controversy
por: Heatwole, Chad, et al.
Publicado: (2008) -
Cytomegalovirus Retinitis in a Patient on Long-term Mycophenolate Mofetil Treatment for Myasthenia Gravis
por: Patel, Shyam, et al.
Publicado: (2020) -
Personality factors in patients with myasthenia gravis: A prospective study
por: Jordan, Berit, et al.
Publicado: (2023) -
A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil
por: Jespersen, Mette Syberg, et al.
Publicado: (2021) -
Immunosuppression With Mycophenolate Mofetil Attenuates Hypertension in an Experimental Model of Autoimmune Disease
por: Taylor, Erin B., et al.
Publicado: (2017)